Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025
I'm PortAI, I can summarize articles.
Aardvark Therapeutics Inc. will present new data on its obesity drug pipeline at ObesityWeek 2025 in Atlanta from November 4-7, 2025. The company will showcase investigational compounds ARD-101 and WE-868, with presentations by CSO Timothy Kieffer and CEO Tien Lee on November 4. An investor webinar is scheduled for November 5 to discuss the data and updates on ARD-101’s development in Prader-Willi Syndrome, with an archived recording available for a month post-event.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments